Physicochemical Properties
| Molecular Formula | C15H13CL2NO3 |
| Molecular Weight | 326.174622297287 |
| Exact Mass | 325.027 |
| CAS # | 1808986-37-9 |
| PubChem CID | 122189958 |
| Appearance | White to off-white solid powder |
| LogP | 3.2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 4 |
| Heavy Atom Count | 21 |
| Complexity | 356 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C(C1C=CC(Cl)=CC=1Cl)C(=O)NCC1C=CC(O)=C(O)C=1 |
| InChi Key | BKPCQXGBKRAJDW-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C15H13Cl2NO3/c16-11-3-2-10(12(17)7-11)6-15(21)18-8-9-1-4-13(19)14(20)5-9/h1-5,7,19-20H,6,8H2,(H,18,21) |
| Chemical Name | 2-(2,4-dichlorophenyl)-N-[(3,4-dihydroxyphenyl)methyl]acetamide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | ERCC1-XPF-IN-2 (compound 13) (0-100 µM) has DNase I and FEN-1 activity with IC50 values >100 and >100 µM, respectively [1]. The binding kinetics of ERCC1-XPF-IN-2 are sluggish, with a Kd value of about 30 µM [1]. Hep-G2 cells are not affected by ERCC1-XPF-IN-2 at concentrations up to 10 µM. Mice and humans have relatively short half-lives (t1/2 values of 23 minutes and 28 minutes, respectively) for their microsomes. Nucleotide excision repair (NER) in A375 cells is inhibited by ERCC1-XPF-IN-2 (0-60 µM; 24 h) with an IC50 value of 15.6 µM [1]. Without causing toxicity, ERCC1-XPF-IN-2 (0-60 µM) boosts cisplatin action [1]. Delays in DNA repair are caused by ERCC1-XPF-IN-2 (10 µM; 6h), which right-shifts more γH2AX foci per cell [1]. |
| Cell Assay |
Cytotoxicity Assay[1] Cell Types: A375 Cell Tested Concentrations: 0-60 µM Incubation Duration: Experimental Results: Did not show any toxicity and increased cisplatin activity to 1.5 times (PF50). |
| References |
[1]. Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF. Bioorg Med Chem Lett. 2015 Oct 1;25(19):4097-103. |
Solubility Data
| Solubility (In Vitro) | DMSO : ≥ 250 mg/mL (~766.47 mM) |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0659 mL | 15.3294 mL | 30.6589 mL | |
| 5 mM | 0.6132 mL | 3.0659 mL | 6.1318 mL | |
| 10 mM | 0.3066 mL | 1.5329 mL | 3.0659 mL |